Literature DB >> 8648775

Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.

S E Lerner1, M L Blute, E J Bergstralh, D G Bostwick, J T Eickholt, H Zincke.   

Abstract

PURPOSE: Up to 26% of patients with pathologically organ confined prostate cancer will experience clinical progression after radical prostatectomy. We attempted to identify patients at greatest risk for future clinical failure despite a favorable pathological outcome.
MATERIALS AND METHODS: The study group included 904 patients treated with bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for disease confined to the prostate gland. Preoperative serum prostate specific antigen (PSA), clinical stage, pathological grade and stage, and deoxyribonucleic acid (DNA) ploidy were evaluated by multivariate analysis to determine relative value in predicting treatment failure. A prognostic scoring system was created using the regression coefficients from the Cox multivariate model to classify patients further according to risk of progression.
RESULTS: Preoperative PSA concentration, clinical stage, grade and DNA ploidy were significant univariate predictors of progression (p < 0.0001), whereas pathological stage was not (p = 0.2). Multivariate analysis identified pathological grade (p < 0.0001), preoperative serum PSA concentration (p = 0.0006) and DNA ploidy (p = 0.0089) as independent predictors of progression. The prognostic scoring system separated the patients into 5 distinct groups. Patients with the lowest score had a 92% progression-free survival rate at 5 years, compared to only 39% of those with the highest scores.
CONCLUSIONS: Patients believed to be at higher risk for cancer progression despite having organ confined disease might be targeted for adjuvant therapy and closer surveillance, while those at low risk may be followed less often.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648775

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  Selecting treatment for high-risk, localized prostate cancer: the case for radiation therapy.

Authors:  Robert Meier; Michael K Brawer
Journal:  Rev Urol       Date:  2002

2.  Early diagnosis and staging of prostate cancer.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2003

3.  Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era.

Authors:  Ahva Shahabi; Raj Satkunasivam; Inderbir S Gill; Gary Lieskovsky; Sia Daneshmand; Jacek K Pinski; Mariana C Stern
Journal:  Can Urol Assoc J       Date:  2016-01-14       Impact factor: 1.862

4.  Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence.

Authors:  Jason P Izard; Lawrence D True; Philip May; William J Ellis; Paul H Lange; Bruce Dalkin; Daniel W Lin; Rodney A Schmidt; Jonathan L Wright
Journal:  Am J Surg Pathol       Date:  2014-03       Impact factor: 6.394

5.  Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database.

Authors:  David E Kang; Nicholas J Fitzsimons; Joseph C Presti; Christopher J Kane; Martha K Terris; William J Aronson; Christopher L Amling; Stephen J Freedland
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

Review 6.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

7.  Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q.

Authors:  Daniel J Schaid; Janet L Stanford; Shannon K McDonnell; Miia Suuriniemi; Laura McIntosh; Danielle M Karyadi; Erin E Carlson; Kerry Deutsch; Marta Janer; Lee Hood; Elaine A Ostrander
Journal:  Hum Genet       Date:  2007-05-08       Impact factor: 4.132

8.  Survival in prostate cancer patients > or = 70 years after radical prostatectomy and comparison to younger patients.

Authors:  Jesco Pfitzenmaier; Sascha Pahernik; Stephan Buse; Axel Haferkamp; Nenad Djakovic; Markus Hohenfellner
Journal:  World J Urol       Date:  2009-04-26       Impact factor: 4.226

9.  Prostate Cancer Expression Profiles of Cytoplasmic ERβ1 and Nuclear ERβ2 are Associated with Poor Outcomes following Radical Prostatectomy.

Authors:  George R Schade; Sarah K Holt; Xiaotun Zhang; Dan Song; Jonathan L Wright; Shanshan Zhao; Suzanne Kolb; Hung-Ming Lam; Linda Levin; Yuet-Kin Leung; Shuk-Mei Ho; Janet L Stanford
Journal:  J Urol       Date:  2016-01-22       Impact factor: 7.450

10.  Prediction of biochemical failure in localized carcinoma of prostate after radical prostatectomy by neuro-fuzzy.

Authors:  Neeraj Kumar Goyal; Abhay Kumar; Rajiba L Acharya; Udai Shankar Dwivedi; Sameer Trivedi; Pratap Bahadur Singh; T N Singh
Journal:  Indian J Urol       Date:  2007-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.